About Astrocyte Pharmaceuticals Inc
Astrocyte Pharmaceuticals Inc. is a new drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.
Astrocyte Pharmaceuticals is developing a proprietary small molecule pharmaceutical agent for acute administration to patients who have suffered a TBI, concussion or stroke. This product would be administered by intravenous injection by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. The approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts as the company focuses on a non-neuronal cell type, the astrocyte, which is the most common cell type in the human brain and has only recently received broader attention as important cellular targets for therapeutic research. Astrocytes are the natural caretaker cells in the brain and their activation enhances multiple natural healing mechanisms including protection against edema, glutamate excitotoxicity and oxidative stress. The company has data demonstrating significant neuroprotective efficacy in multiple rodent models, at time points as late as 24 hours post injury.
State of Ownership
Former Head of Communities, Springer Nature
Managing Director, Thoroughly Good Consulting
Sales Account Executive, Springer Nature
CTO & Co-Founder, Zapnito
CEO & Co-Founder, Zapnito